Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc.

Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ.

Mol Endocrinol. 2004 May;18(5):1096-108. Epub 2004 Feb 12.

PMID:
14963108
2.

MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways.

Cheskis BJ, Greger J, Cooch N, McNally C, Mclarney S, Lam HS, Rutledge S, Mekonnen B, Hauze D, Nagpal S, Freedman LP.

Steroids. 2008 Oct;73(9-10):901-5. doi: 10.1016/j.steroids.2007.12.028. Epub 2008 Jan 4. Review.

PMID:
18261753
4.

Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase.

Greger JG, Fursov N, Cooch N, McLarney S, Freedman LP, Edwards DP, Cheskis BJ.

Mol Cell Biol. 2007 Mar;27(5):1904-13. Epub 2006 Dec 28. Retraction in: Mol Cell Biol. 2010 Mar;30(6):1568.

5.
6.

MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation.

Kayahara M, Ohanian J, Ohanian V, Berry A, Vadlamudi R, Ray DW.

Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1047-55. doi: 10.1152/ajpendo.90429.2008. Epub 2008 Aug 5.

7.
9.

Characterization of MNAR expression.

Greger JG, Guo Y, Henderson R, Ross JF, Cheskis BJ.

Steroids. 2006 Apr;71(4):317-22. Epub 2005 Nov 16.

PMID:
16297421
10.
11.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

13.

Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells.

Ballaré C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M.

Mol Cell Biol. 2003 Mar;23(6):1994-2008.

14.

Cloning, expression, and localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-alpha- but not in gonadotropin-releasing hormone-positive neurons.

Khan MM, Hadman M, Wakade C, De Sevilla LM, Dhandapani KM, Mahesh VB, Vadlamudi RK, Brann DW.

Endocrinology. 2005 Dec;146(12):5215-27. Epub 2005 Sep 1.

PMID:
16141397
15.

Estrogen Receptor Folding Modulates cSrc Kinase SH2 Interaction via a Helical Binding Mode.

Nieto L, Tharun IM, Balk M, Wienk H, Boelens R, Ottmann C, Milroy LG, Brunsveld L.

ACS Chem Biol. 2015 Nov 20;10(11):2624-32. doi: 10.1021/acschembio.5b00568. Epub 2015 Sep 18.

PMID:
26352092
16.

Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Burow ME.

Cancer Biol Ther. 2012 Sep;13(11):1026-33. doi: 10.4161/cbt.20992. Epub 2012 Jul 24.

17.
18.

CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Padmanabhan RA, Nirmala L, Murali M, Laloraya M.

Mol Endocrinol. 2011 Sep;25(9):1499-512. doi: 10.1210/me.2011-0008. Epub 2011 Jun 23.

PMID:
21700719
19.

Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.

Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ.

Mol Endocrinol. 2002 Jan;16(1):116-27.

PMID:
11773443
20.
Items per page

Supplemental Content

Write to the Help Desk